Overview

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This is a randomized , double-blind, placebo-controlled study of approximately 70 patients with ulcerative colitis.
Phase:
Phase 1
Details
Lead Sponsor:
Genentech, Inc.
Treatments:
Etrolizumab